๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 36 Beijing 20 Guangzhou 11 Tianjin 11 Jinan 6
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai36 Beijing20 Guangzhou11 Tianjin11 Jinan6
All 24 locations
Target enrolment
to

Trials with a site in Guangzhou

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects
NCT07446153Solid Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
282
Guangzhou, Shenyang
2026-03-19
Recruiting
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer
NCT07241767Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
200
Guangzhou
2025-11-12
Recruiting
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
NCT07175220Locally Advanced or Metastatic Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
200
Guangzhou
2025-10-09
Recruiting
Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis
NCT06775340Adolescent Asthma
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
252
Guangzhou
2025-01-22
Recruiting
Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
NCT06735144Malignant Solid Tumor
DrugFH-006
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
200
Guangzhou
2024-12-23
Recruiting
A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients
NCT06344091Local Analgesia Via Infiltration
Jiangsu HengRui Medicine Co., Ltd.
Phase 4
232
Guangzhou
2024-05-21
Recruiting
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
NCT05473624Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
NCT05424835HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
381
Guangzhou
2022-08-04
Active, closed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04691804Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Shanghai, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2021-03-18
Recruiting
A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
NCT04316364Non-Small-Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
537
Beijing, Guangzhou, Zhengzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2020-07-14
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

8 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 11 studies
PhaseStudiesRecruitingShare
Phase 23327.3%
Phase 33127.3%
Phase 1/22218.2%
Phase 1119.1%
Phase 2/3109.1%
Phase 4119.1%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Jiangsu HengRui Medicine Co., Ltd.118
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.